Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model.
作者信息
Zhou Yueqin, Carmona Sharon, Muhammad A K M G, Bell Shaughn, Landeros Jesse, Vazquez Michael, Ho Ritchie, Franco Antonietta, Lu Bin, Dorn Gerald W, Wang Shaomei, Lutz Cathleen M, Baloh Robert H
出版信息
J Clin Invest. 2021 Jan 19;131(2). doi: 10.1172/JCI147307.
Abstract
摘要
相似文献
1
Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model.
J Clin Invest. 2021 Jan 19;131(2). doi: 10.1172/JCI147307.
2
Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A.
Brain. 2010 May;133(Pt 5):1460-9. doi: 10.1093/brain/awq082.
3
Mitofusin 2 expression dominates over mitofusin 1 exclusively in mouse dorsal root ganglia - a possible explanation for peripheral nervous system involvement in Charcot-Marie-Tooth 2A.
Folia Neuropathol. 2014;52(4):436-42. doi: 10.5114/fn.2014.47845.
4
Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease.
Brain. 2016 Jan;139(Pt 1):62-72. doi: 10.1093/brain/awv311. Epub 2015 Oct 24.
5
Charcot-Marie-Tooth neuropathy type 2A: novel mutations in the mitofusin 2 gene (MFN2).
BMC Med Genet. 2006 Jun 8;7:53. doi: 10.1186/1471-2350-7-53.
6
Early onset Charcot-Marie-Tooth neuropathy type 2A and severe developmental delay: expanding the clinical phenotype of MFN2-related neuropathy.
J Peripher Nerv Syst. 2015 Dec;20(4):415-8. doi: 10.1111/jns.12148.
7
Genetic epidemiology of Charcot-Marie-Tooth disease.
Acta Neurol Scand Suppl. 2012(193):iv-22. doi: 10.1111/ane.12013.
8
Fifteen-year longitudinal follow-up of a patient with severe early-onset Charcot-Marie-Tooth disease type 2A.
Muscle Nerve. 2018 May;57(5):E126-E128. doi: 10.1002/mus.26047. Epub 2018 Jan 26.
9
Finding a new balance to cure Charcot-Marie-Tooth 2A.
J Clin Invest. 2019 Mar 18;129(4):1533-1535. doi: 10.1172/JCI127820.
10
A Sporadic Case of Charcot-Marie-Tooth Disease Type 2 with Left Vocal Fold Palsy due to Mitofusin 2 Mutation.
Intern Med. 2019 Jul 15;58(14):2091-2093. doi: 10.2169/internalmedicine.2318-18. Epub 2019 Apr 17.
引用本文的文献
1
Charcot-Marie-Tooth type 2A in vivo models: Current updates.
J Cell Mol Med. 2024 May;28(9):e18293. doi: 10.1111/jcmm.18293.
2
Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot-Marie-Tooth type 2A.
Cell Mol Life Sci. 2023 Nov 25;80(12):373. doi: 10.1007/s00018-023-05018-w.
3
A human mitofusin 2 mutation can cause mitophagic cardiomyopathy.
Elife. 2023 Nov 1;12:e84235. doi: 10.7554/eLife.84235.
4
Activating mitofusins interrupts mitochondrial degeneration and delays disease progression in SOD1 mutant amyotrophic lateral sclerosis.
Hum Mol Genet. 2023 Mar 20;32(7):1208-1222. doi: 10.1093/hmg/ddac287.
5
Predicting Mitochondrial Dynamic Behavior in Genetically Defined Neurodegenerative Diseases.
Cells. 2022 Mar 19;11(6):1049. doi: 10.3390/cells11061049.
6
Therapeutic Strategies Targeting Mitochondrial Calcium Signaling: A New Hope for Neurological Diseases?
Antioxidants (Basel). 2022 Jan 15;11(1):165. doi: 10.3390/antiox11010165.
Zotero 插件